Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Myelodysplastic-Myeloproliferative Diseases × Sunitinib × 1 year × Clear all

Sponsor

Conditions

Carcinoma, Renal Cell 16 Gastrointestinal Stromal Tumors 7 Neoplasms 4 Multiple Myeloma 3 Kidney Neoplasms 3 Urologic Neoplasms 2 Osteosarcoma 2 Neoplasm Metastasis 2 Meningioma 2 Lymphoma, Non-Hodgkin 2 Kidney Diseases 2 Gastrointestinal Neoplasms 2 Carcinoma 2 Adenoma, Islet Cell 2 Uveal Melanoma 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Thymoma 1 Thoracic Neoplasms 1 Somatostatinoma 1 Solid Tumors Refractory to Standard Therapy 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Prostatic Neoplasms 1 Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 1 Pelvic Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Nervous System Neoplasms 1

Interventions

Specimen Handling 7 Biopsy 6 Cyclophosphamide 5 ruxolitinib 4 Mycophenolic Acid 4 Busulfan 4 fludarabine phosphate 3 fludarabine 3 Whole-Body Irradiation 3 Tacrolimus 3 Melphalan 3 Injections 3 Decitabine 3 Cyclosporine 3 Azacitidine 3 venetoclax 2 decitabine and cedazuridine drug combination 2 Sirolimus 2 Methotrexate 2 Granulocyte Colony-Stimulating Factor 2 veliparib 1 tocilizumab 1 tagraxofusp 1 posaconazole 1 peginterferon alfa-2b 1 onvansertib 1 merphos 1 iadademstat 1 gilteritinib 1 fedratinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡